SCHEMBL10330736

SCHEMBL10330736

CCCCOC(=O)CN1CCC(=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 2/20 0.42
TSHR P16473 2/20 0.41
NAAA Q02083 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
ALOX15 P16050 1/20 0.40
LMNA P02545 1/20 0.40
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.39
PRKCA P17252 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30839344 0.86 MEN1 (0.49) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL16607366 0.86 MEN1 (0.49) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL10382093 0.83 ALDH1A1 (0.53) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL7797419 0.83 GSK3B (0.49) MEN1KMT2AALDH1A1SMN1; SMN2ALOX15
SCHEMBL12120089 0.81 ALDH1A1 (0.55) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL10943385 0.81 ALDH1A1 (0.55) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL17532246 0.80 ALDH1A1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL10852328 0.80 THRA (0.47) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL16607367 0.80 ALDH1A1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL11855822 0.80 NAAA (0.60) MEN1KMT2AALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222402-B2 Preparation process BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-17 US disclosed
US-8222402-B2 Preparation process BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-17 US disclosed
US-20110071286-A1 NOVEL PREPARATION PROCESS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-24 US disclosed
US-20110071286-A1 NOVEL PREPARATION PROCESS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-24 US disclosed
WO-2009021942-A1 NOVEL PREPARATION PROCESS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071286-A1 NOVEL PREPARATION PROCESS RPLP1, RPLP2, CYP1B1 MEN1 353/4885KMT2A 4390/4885ALDH1A1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.